In addition, LG-MSC-Exos influenced the secretory profile of T cells, leading to reduced production of inflammatory cytokines (IL-17A, IFN-γ, IL-6, and TNF-α) and elevated the production of immunosuppressive TGF-β and IL-10, confirming therapeutic potential of LG-MSC-Exos in the attenuation of T-cell–driven eye inflammation [37]. The gene discussed is IL6; the disease is eye inflammation.